Skip to main content
Premium Trial:

Request an Annual Quote

DeCode s Q1 Revenues Increase 9 Percent

NEW YORK, May 16 – DeCode Genetics’ revenues rose nine percent to $5.0 million in the first quarter as milestone revenues increased.

Expenditures for the quarter more than doubled to $20.2 million, compared with $9.2 million in the year ago period as the company expanded its research activities and incurred higher general and administrative expenses.

During the first quarter, DeCode delivered schizophrenia and peripheral arterial occlusive targets to Roche as part of its alliance to develop diagnostics. The company said it expects to post near- and medium-term revenue growth stemming from milestone payments related to the five-year alliance, details of which are scheduled to be announced during the next few weeks.

DeCode of Reykjavik, Iceland, said it also entered new partnerships in gene discovery, pharmacogenomics, database services, and bioinformatics.

The company had net losses of  $16.1 million, or 37 cents a share, compared with net losses of $6.9 million, or 23 cents a share, a year ago.

As of the end of March DeCode had about $172 million in cash and cash equivalents.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.